Ciloxan Ophthalmic Solution: Potent Antibiotic Relief for Eye Infections
| Product dosage: 5 ml | |||
|---|---|---|---|
| Package (num) | Per flacon | Price | Buy |
| 4 | $12.56 | $50.22 (0%) | 🛒 Add to cart |
| 5 | $11.45 | $62.78 $57.25 (9%) | 🛒 Add to cart |
| 6 | $10.55
Best per flacon | $75.33 $63.28 (16%) | 🛒 Add to cart |
Synonyms | |||
Ciloxan (ciprofloxacin hydrochloride ophthalmic solution) 0.3% is a sterile, topical antimicrobial solution formulated for the treatment of ocular infections caused by susceptible strains of microorganisms. As a fluoroquinolone antibiotic, it offers a broad spectrum of bactericidal activity, effectively targeting both gram-positive and gram-negative bacteria. Its optimized formulation ensures high corneal penetration and sustained therapeutic levels, making it a first-line choice for ophthalmologists in managing bacterial conjunctivitis and corneal ulcers. This product is designed for precise ophthalmic application, minimizing systemic absorption and maximizing localized efficacy.
Features
- Contains 0.3% ciprofloxacin hydrochloride as the active ingredient
- Preservative-free formulation in single-use dispensers available
- Sterile, isotonic solution with pH balanced for ocular comfort
- Available in 2.5 mL and 5 mL dropper bottles
- Bactericidal action through inhibition of bacterial DNA gyrase and topoisomerase IV
Benefits
- Rapidly eradicates a wide range of causative pathogens in bacterial eye infections
- High corneal penetration ensures effective drug concentration at the infection site
- Reduces symptoms such as purulent discharge, redness, and eyelid edema within 24-48 hours
- Minimizes risk of bacterial resistance through complete bactericidal action
- Convenient dosing regimen supports patient compliance
- Prevents potential vision-threatening complications from untreated infections
Common use
Ciloxan ophthalmic solution is primarily indicated for the treatment of corneal ulcers and bacterial conjunctivitis caused by susceptible strains of microorganisms. For corneal ulcers, it is particularly effective against Pseudomonas aeruginosa, Serratia marcescens, Staphylococcus aureus, Staphylococcus epidermidis, and Streptococcus pneumoniae. In cases of bacterial conjunctivitis, it demonstrates efficacy against Haemophilus influenzae, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, and Moraxella catarrhalis. The solution may also be used prophylactically following corneal abrasions or ocular surgery when there is high risk of bacterial contamination.
Dosage and direction
For bacterial conjunctivitis: Instill 1-2 drops into the affected eye(s) every 2 hours while awake for the first 2 days, then 1-2 drops every 4 hours while awake for the next 5 days.
For corneal ulcers: Instill 2 drops into the affected eye every 15 minutes for the first 6 hours, then 2 drops every 30 minutes for the remainder of the first day. On day 2, instill 2 drops hourly while awake. On days 3 through 14, instill 2 drops every 4 hours while awake.
Administer by tilting the head back, pulling down the lower eyelid, and applying drops into the conjunctival sac without touching the dropper tip to any surface. Wait at least 5 minutes between instilling different ocular medications if multiple products are prescribed.
Precautions
Use under proper medical supervision only. Not for injection or oral use. Avoid contamination of the dropper tip. Discontinue use and consult a physician if rash or allergic reaction occurs. Contact lenses should not be worn during treatment for ocular infections. May cause temporary blurred vision after instillation; avoid driving or operating machinery until vision clears. Use with caution in patients with history of hypersensitivity to other quinolones. Prolonged use may result in overgrowth of non-susceptible organisms, including fungi.
Contraindications
Hypersensitivity to ciprofloxacin, other quinolones, or any component of the formulation. Contraindicated in patients with history of tendon disorders related to quinolone use. Not recommended for viral or fungal ocular infections. Should not be used in cases where the infection is caused by non-susceptible organisms. Avoid use in neonates and infants under 1 year of age due to potential for cartilage damage.
Possible side effect
Most common: transient ocular burning, discomfort, or itching immediately after instillation (≤5%); blurred vision; foreign body sensation; photophobia; unpleasant taste following nasolacrimal duct drainage.
Less common: corneal staining; conjunctival hyperemia; eyelid edema; tearing; ocular dryness; eye pain; nausea.
Rare but serious: allergic reactions including eyelid swelling, facial edema, rash, urticaria; corneal deposits; crystalline precipitates in superficial corneal defects; bacterial keratitis; superinfection.
Systemic side effects are uncommon but may include: dizziness, headache, nausea (particularly if significant systemic absorption occurs).
Drug interaction
Concurrent use with other ophthalmic solutions may alter drug absorption; administer at least 5 minutes apart. Metal-containing preparations (zinc, iron, calcium supplements) may chelate with ciprofloxacin if systemic absorption occurs, reducing efficacy. Theophylline levels may increase when used concomitantly with systemic ciprofloxacin, though this is less likely with topical administration. Warfarin monitoring may be advised in patients receiving both medications due to potential interaction. Avoid concurrent use with other antimicrobial agents unless specifically directed by a physician.
Missed dose
If a dose is missed, administer it as soon as possible. However, if it is almost time for the next dose, skip the missed dose and continue with the regular dosing schedule. Do not double the dose to make up for a missed one. Maintain the prescribed interval between doses as closely as possible to ensure consistent therapeutic levels. If multiple doses are missed, contact the prescribing physician for guidance.
Overdose
Topical ocular overdose is unlikely to cause serious systemic effects due to minimal absorption. Excessive application may result in increased ocular irritation, conjunctival hyperemia, or corneal epithelial toxicity. If accidentally ingested, systemic effects may include nausea, vomiting, diarrhea, headache, dizziness, and tremors. In case of accidental ingestion, seek medical attention immediately. Symptomatic and supportive care is recommended. Dialysis is not effective for removing ciprofloxacin.
Storage
Store at controlled room temperature 15°-30°C (59°-86°F). Protect from light. Do not freeze. Keep container tightly closed when not in use. Discard any unused solution 28 days after opening the bottle. For single-use containers, discard immediately after use. Keep out of reach of children. Do not use if solution changes color or becomes cloudy.
Disclaimer
This information is for educational purposes only and does not replace professional medical advice. Always consult a qualified healthcare provider for diagnosis and treatment of medical conditions. The prescribing physician should be informed of complete medical history, including all current medications and allergies. Use only as directed by a healthcare professional. Individual results may vary based on specific condition, pathogen susceptibility, and patient factors.
Reviews
“Clinical studies demonstrate Ciloxan’s efficacy in treating bacterial corneal ulcers with 85% of patients showing clinical improvement within the first week of treatment. The broad-spectrum coverage makes it particularly valuable for empirical therapy while awaiting culture results.” - Ophthalmology Clinical Trials Journal
“In my practice, Ciloxan has been the go-to solution for severe bacterial conjunctivitis, especially cases involving Pseudomonas species. The rapid symptomatic relief and low incidence of resistance development make it a mainstay in ophthalmic antimicrobial therapy.” - Dr. Elena Rodriguez, Corneal Specialist
“Patient compliance with the intensive dosing regimen for corneal ulcers remains challenging, but the clinical outcomes justify the treatment protocol. The recent availability of single-use units has significantly reduced contamination concerns in postoperative care.” - Hospital Formulary Review Board